MYCO:CC News and Press, MYDECINE INNOVATIONS GROUP INC. From 03/03/22

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) , a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today announced that it will be attending three investor conferences in March. The upcoming events include the 34th Annual Ro...

DENVER, March 03, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today announced the ...

The National Endowment for the Arts is sponsoring an arts therapy initiative known as Creative Forces in partnership with the Department of Veterans Affairs and Department of Defense. Art therapies are increasingly being used to treat various brain conditions, including Alzheimer’s,...

A new study has linked the use of psilocybin with a reduction in the likelihood of an individual engaging in criminal behavior. Psilocybin is the active compound found in hallucinogenic mushrooms. Harvard University clinical psychology PhD candidate Grant Jones, the author of the study, ...

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) , a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today announced a positive meeting with the Food and Drug Administration (“FDA”) regarding the company’s ...

DENVER, March 01, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today announced a positiv...

Mydecine announced the inclusion of a patent-pending novel molecule in its family of psilocin analogs, MYCO-005 This molecule features potentially heart-safe microdose-enabling properties, addressing the delivery and stability concerns associated with the first-generation compounds My...

Vancouver Island University (“VIU”) plans to launch its psychedelic-assisted therapy course in September of this year. This will make it the first accredited university in Canada to offer this course for healthcare professionals, under its Faculty of Health and Human Services...

Mydecine (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) , a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, has released a video discussing the company’s fully integrated approach to drug development. “At Mydecine,...

Studies suggest that psychedelics such as psilocybin and MDMA offer health benefits when used to treat patients with depression and PTSD These results have encouraged scientists, psychotherapists, and entrepreneurs, who say that FDA approvals may be on the horizon Mydecine is playing ...